Overview

NCI Definition: A large B-cell non-Hodgkin lymphoma arising in the mediastinum. Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis. Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001) [1]

Clinical Trials

There
are 22 clinical trials
for mediastinal large B-cell lymphoma, of which 19
are
open and 3
are
completed or closed.
Of the
trials that contain
mediastinal large B-cell lymphoma as an inclusion criterion, 9 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), 6 are phase 2 (5 open), 1 is phase 3 (1 open), and 2 are no phase specified (2 open).

BCL2, BCL6, and MYC
are the most frequent gene inclusion
criteria for
mediastinal large B-cell lymphoma clinical trials [3].

Fludarabine, cyclophosphamide, and pembrolizumab
are the most common
interventions in
mediastinal large B-cell lymphoma clinical trials.

Drugs Being Investigated in Mediastinal Large B-Cell Lymphoma Trials by Recruiting Status

Significant Genes in Mediastinal Large B-Cell Lymphoma

ABL1
+

ABL1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
ABL1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1
+

AFF1 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
AFF1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

ALK
+

ALK is an inclusion eligibility criterion in 3 clinical
trials
for mediastinal large B-cell lymphoma, of which 3
are open and 0
are closed.
Of the
trials that contain
ALK status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BCL2
+

BCL2 is an inclusion eligibility criterion in 7 clinical
trials
for mediastinal large B-cell lymphoma, of which 7
are open and 0
are closed.
Of the
trials that contain
BCL2 status and mediastinal large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BCL6
+

BCL6 is an inclusion eligibility criterion in 7 clinical
trials
for mediastinal large B-cell lymphoma, of which 7
are open and 0
are closed.
Of the
trials that contain
BCL6 status and mediastinal large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BCR
+

BCR is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
BCR status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CBFB
+

CBFB is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
CBFB status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CCND1
+

CCND1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
CCND1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DEK
+

DEK is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
DEK status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL
+

ELL is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
ELL status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FLT3
+

FLT3 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
FLT3 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IGH
+

IGH is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
IGH status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IRF4
+

IRF4 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 2
are open and 0
are closed.
Of the
trials that contain
IRF4 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KIT
+

KIT is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
KIT status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A
+

KMT2A is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
KMT2A status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MECOM
+

MECOM is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MECOM status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLF1
+

MLF1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MLF1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLH1
+

MLH1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
MLH1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3
+

MLH3 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
MLH3 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1
+

MLLT1 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
MLLT1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MLLT10
+

MLLT10 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
MLLT10 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MLLT3
+

MLLT3 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
MLLT3 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MLLT4
+

MLLT4 is an inclusion eligibility criterion in 2 clinical
trials
for mediastinal large B-cell lymphoma, of which 1
is open and 1
is closed.
Of the
trials that contain
MLLT4 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MSH2
+

MSH2 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH2 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3
+

MSH3 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH3 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6
+

MSH6 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
MSH6 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC
+

MYC is an inclusion eligibility criterion in 7 clinical
trials
for mediastinal large B-cell lymphoma, of which 7
are open and 0
are closed.
Of the
trials that contain
MYC status and mediastinal large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MYH11
+

MYH11 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
MYH11 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1
+

NPM1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
NPM1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214
+

NUP214 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
NUP214 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PMS1
+

PMS1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
PMS1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2
+

PMS2 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 1
is open and 0
are closed.
Of the
trial that contains
PMS2 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1
+

RPN1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
RPN1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RUNX1
+

RUNX1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
RUNX1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RUNX1T1
+

RUNX1T1 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
RUNX1T1 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53
+

TP53 is an inclusion eligibility criterion in 1 clinical
trial
for mediastinal large B-cell lymphoma, of which 0
are open and 1
is closed.
Of the
trial that contains
TP53 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.